Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
MH Davidson,CM Ballantyne,TA Jacobson,VA Bittner,LT Braun,AS Brown,WV Brown,WC Cromwell,RB Goldberg,JM McKenney,AT Remaley,AD Sniderman,PP Toth,S Tsimikas,PE Ziajka,KC Maki,MR Dicklin
J Clin Lipidol 2011 9;5(5):338-67

Childhood adiposity, adult adiposity, and cardiovascular risk factors.
M Juonala,CG Magnussen,GS Berenson,A Venn,TL Burns,MA Sabin,SR Srinivasan,SR Daniels,PH Davis,W Chen,C Sun,M Cheung,JS Viikari,T Dwyer,OT Raitakari
N Engl J Med 2011 11;365(20):1876-85

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial.
MA Nauck,S Del Prato,JJ Meier,S Durán-García,K Rohwedder,M Elze,SJ Parikh
Diabetes Care 2011 9;34(9):2015-22

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.
RA de Boer,DJ Lok,T Jaarsma,P van der Meer,AA Voors,HL Hillege,DJ van Veldhuisen
Ann Med 2011 2;43(1):60-8

Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia.
S Yagi,M Akaike,K Aihara,T Iwase,K Ishikawa,S Yoshida,Y Sumitomo-Ueda,K Kusunose,T Niki,K Yamaguchi,K Koshiba,Y Taketani,N Tomita,H Yamada,T Soeki,T Wakatsuki,T Matsumoto,M Sata
Am J Cardiol 2011 6;107(11):1644-9

Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists.
M Yoshika,Y Komiyama,M Masuda,T Yokoi,H Masaki,H Ohkura,H Takahashi
Clin Exp Hypertens 2010 1;32(6):341-6

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet 2011 6;():

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
L Yvan-Charvet,J Kling,T Pagler,H Li,B Hubbard,T Fisher,CP Sparrow,AK Taggart,AR Tall
Arterioscler Thromb Vasc Biol 2010 7;30(7):1430-8

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.
JH Best,KS Boye,RR Rubin,D Cao,TH Kim,M Peyrot
Diabet Med 2009 7;26(7):722-8

Pioglitazone for diabetes prevention in impaired glucose tolerance.
RA DeFronzo,D Tripathy,DC Schwenke,M Banerji,GA Bray,TA Buchanan,SC Clement,RR Henry,HN Hodis,AE Kitabchi,WJ Mack,S Mudaliar,RE Ratner,K Williams,FB Stentz,N Musi,PD Reaven
N Engl J Med 2011 3;364(12):1104-15

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
E Ferrannini,SJ Ramos,A Salsali,W Tang,JF List
Diabetes Care 2010 10;33(10):2217-24

Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial.
SK Garg,PJ Ritchie,EG Moser,JK Snell-Bergeon,BJ Freson,RM Hazenfield
Diabetes Obes Metab 2011 2;13(2):137-43

Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism.
G Brufau,F Stellaard,K Prado,VW Bloks,E Jonkers,R Boverhof,F Kuipers,EJ Murphy
Hepatology 2010 10;52(4):1455-64

Consumption of Added Sugars and Indicators of Cardiovascular Disease Risk Among US Adolescents.
JA Welsh,A Sharma,SA Cunningham,MB Vos
Circulation 2011 1;():

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
CJ Bailey,JL Gross,A Pieters,A Bastien,JF List
Lancet 2010 6;375(9733):2223-33

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.
MJ Bolland,A Avenell,JA Baron,A Grey,GS MacLennan,GD Gamble,IR Reid
BMJ 2010 1;341():c3691